Nanomaterials in the treatment of degenerative intellectual and developmental disabilities

Abstract

Nanoparticles (NPs) are at the forefront as they are providing unprecedented solutions to obstacles and issues in treating neurodegenerative diseases. Due to their size, surface characteristics, and ability to be functionalized, these carriers can directly deliver therapeutics across what is considered one of the main barriers to central nervous system (CNS) treatment, the blood-brain barrier (BBB). Through nanotechnology, anti-disease agents such as Alzheimer’s, Parkinson’s, and Huntington’s therapies become more bioavailable, specific in action, and with fewer side effects. The NPs serve as molecular carriers that facilitate transport across the BBB by receptor-mediated transcytosis or by disruption of the barrier with a view to properly delivering drugs to the neural tissues. Some of the therapeutic applications of nanotechnology also present the concept of molecular medicine since the NPs are designed to deliver drugs in accordance with specific biomolecule signals. Besides the therapeutic applications, NPs replace the traditional contrast media for magnetic resonance imaging (MRI) and positron emission tomography (PET) scans for better diagnosis as well as disease tracking in the early stages. In addition, their effects on solubility increase the therapeutic potential of earlier useless compounds, and the preservation of bioactive molecules from degradation increases the therapeutic capacity of medications. Neurodegenerative disorders are marked by oxidative stress and inflammation that contribute to the disease severity; thus, liposomes, dendrimers, and polymeric NPs encapsulate antioxidants and anti-inflammatory compounds, so they target the areas most affected by the disease. Such sophisticated systems minimize the extension of neuronal deterioration and enhance the lot of such patients. The “theranostic” NPs allow for continuous diagnosis and treatment by containing both diagnostic and therapeutic features. These have created unprecedented opportunities to meet the unmet needs in CNS disorders and may revolutionize the evolution of managing neurodegenerative diseases and innovative neuroimaging procedures in the future.

Keywords

Nanoparticles in medicine / blood-brain barrier / neurodegenerative diseases / nanotechnology-based therapy / bioavailability enhancement / neuroimaging techniques

References

[1] Kumar R, Aadil KR, Mondal K, Mishra YK, Oupicky D, Ramakrishna S, et al. Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology. Crit Rev Biotechnol. 2022; 42: 1180-212.

[2] Asil SM, Ahlawat J, Barroso GG, Narayan M. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. Biomater Sci. 2020; 8: 4109-28.

[3] An Z, Yan J, Zhang Y, Pei R. Applications of nanomaterials for scavenging reactive oxygen species in the treatment of central nervous system diseases. J Mater Chem B. 2020; 8: 8748-67.

[4] Ngowi EE, Wang Y, Qian L, Helmy YASH, Anyomi B, Li T, et al. The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders. Front Bioeng Biotechnol. 2021; 9: 629832.

[5] Martinelli C, Pucci C, Battaglini M, Marino A, Ciofani G. Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases. Adv Healthc Mater. 2020; 9: e1901589.

[6] Bhattacharya T, Soares GABE, Chopra H, Rahman MM, Hasan Z, Swain SS, et al. Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders. Materials (Basel). 2022; 15: 804.

[7] He X, Zhu Y, Ma B, Xu X, Huang R, Cheng L, et al. Bioactive 2D nanomaterials for neural repair and regeneration. Adv Drug Deliv Rev. 2022; 187: 114379.

[8] Pichla M, Bartosz G, Sadowska-Bartosz I. The Antiaggregative and Antiamyloidogenic Properties of Nanoparticles: A Promising Tool for the Treatment and Diagnostics of Neurodegenerative Diseases. Oxid Med Cell Longev. 2020; 2020: 3534570.

[9] Martano S, Matteis VD, Cascione M, Rinaldi R. Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration. Nanomaterials (Basel). 2022; 12: 2337.

[10] Bordoni M, Scarian E, Rey F, Gagliardi S, Carelli S, Pansarasa O, et al. Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach. Int J Mol Sci. 2020; 21: 3243.

[11] Muheem A, Jahangir MA, Jaiswal CP, Jafar M, Ahmad MZ, Ahmad J, et al. Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders. Curr Drug Metab. 2021; 22: 263-79.

[12] Abdel-Mageed HM, AbuelEzz NZ, Radwan RA, Mohamed SA. Nanoparticles in nanomedicine: a comprehensive updated review on current status, challenges and emerging opportunities. J Microencapsul. 2021; 38: 414-36.

[13] Suhag D, Kaushik S, Taxak VB. Challenges and future directions. In: Handbook of Biomaterials for Medical Applications. Singapore: Springer; 2024. pp. 329-55.

[14] Lin Y, Li Q, Wang L, Guo Q, Liu S, Zhu S, et al. Advances in regenerative medicine applications of tetrahedral framework nucleic acid-based nanomaterials: an expert consensus recommendation. Int J Oral Sci. 2022; 14: 51.

[15] Migliore L, Uboldi C, Bucchianico SD, Coppedè F. Nanomaterials and neurodegeneration. Environ Mol Mutagen. 2015; 56: 149-70.

[16] Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci. 2010; 1184: 154-72.

[17] Spuch C, Saida O, Navarro C. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat Drug Deliv Formul. 2012; 6: 2-18.

[18] Umar A, Khan MS, Wajid M, Khan MU. Dose-dependent effects of cobalt nanoparticles on antioxidant systems, hematological parameters, and organ morphology in albino mice. BioNanoScience. 2024; 14: 3078-98.

[19] Khan T, Umar A, Waheed A, Khan MS, Wajid M, Ullah H. Assessment of possible potential toxicity risks in albino mice exposed to amine-coated silver nanoparticles. Kuwait J Sci. 2024; 51: 100172.

[20] Rafique S, Khan MS, Unar R, Wajid M, Waheed A, Umar A. Evaluation of mental health and anxiety level among hepatitis C patients during COVID-19 pandemic in Pakistan. Egypt Liver J. 2021; 11: 50.

[21] Umar A, Khan MS, Sehgal SA, Jafar K, Ahmad S, Waheed A, et al. Epidemiological studies of sleep disorder in educational community of Pakistani population, its major risk factors and associated diseases. PLoS One. 2022; 17: e0266739.

[22] Umar A, Khan MS, Wajid M, Ullah H. Biocompatibility, antimicrobial efficacy, and therapeutic potential of cobalt carbonate nanoparticles in wound healing, sex hormones, and metabolic regulation in diabetic albino mice. Biochem Biophys Res Commun. 2024; 734: 150773.

[23] Teleanu RI, Gherasim O, Gherasim TG, Grumezescu V, Grumezescu AM, Teleanu DM. Nanomaterial-Based Approaches for Neural Regeneration. Pharmaceutics. 2019; 11: 266.

[24] Kanwar JR, Sun X, Punj V, Sriramoju B, Mohan RR, Zhou S, et al. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine. 2012; 8: 399-414.

[25] Mazibuko Z, Choonara YE, Kumar P, Du Toit LC, Modi G, Naidoo D, et al. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. J Pharm Sci. 2015; 104: 1213-29.

[26] Cano A, Sánchez-López E, Ettcheto M, López-Machado A, Espina M, Souto EB, et al. Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine (Lond). 2020; 15: 1239-61.

[27] Hassanzadeh P. Nanopharmaceuticals: Innovative theranostics for the neurological disorders. Biomedical Reviews. 2014; 25: 25-34.

[28] Chaudhury K, Kumar V, Kandasamy J, RoyChoudhury S. Regenerative nanomedicine: current perspectives and future directions. Int J Nanomedicine. 2014; 9: 4153-67.

[29] Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007; 32: 1054-82.

[30] Zhou S, Li Y, Wu Q, Gong C. Nanotechnology-based CRISPR/Cas9 delivery system for genome editing in cancer treatment. MedComm-Biomaterials and Applications. 2024; 3: e70.

[31] Gilmore JL, Yi X, Quan L, Kabanov AV. Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol. 2008; 3: 83-94.

[32] Halim A, Qu K, Zhang X, Huang N. Recent Advances in the Application of Two-Dimensional Nanomaterials for Neural Tissue Engineering and Regeneration. ACS Biomater Sci Eng. 2021; 7: 3503-29.

[33] Burns JD, Cervantes-Arslanian AM, editors. Neurologic Emergencies, An Issue of Neurologic Clinics. 1st ed. Elsevier; 2021.

[34] Pampaloni NP, Giugliano M, Scaini D, Ballerini L, Rauti R. Advances in Nano Neuroscience: From Nanomaterials to Nanotools. Front Neurosci. 2019; 12: 953.

[35] Polak P, Shefi O. Nanometric agents in the service of neuroscience: Manipulation of neuronal growth and activity using nanoparticles. Nanomedicine. 2015; 11: 1467-79.

[36] Lowe TL, Agrahari V, Kannan RM, Kannan S. Nanotechnology enabled regenerative medicine for neurological disorders. Adv Drug Deliv Rev. 2019; 148: 1-2.

[37] Pena SA, Iyengar R, Eshraghi RS, Bencie N, Mittal J, Aljohani A, et al. Gene therapy for neurological disorders: challenges and recent advancements. J Drug Target. 2020; 28: 111-28.

[38] Khan T, Umar A, Subhan Z, Khan MS, Ali HZ, Ullah H, et al. Therapeutic Potential of Novel Silver Carbonate Nanostructures in Wound Healing and Antibacterial Activity Against Pseudomonas chengduensis and Staphylococcus aureus . Pharmaceuticals (Basel). 2024; 17: 1471.

[39] Masoudi Asil S, Ahlawat J, Guillama Barroso G, Narayan M. Application of nanotechnology in stem-cell-based therapy of neurodegenerative diseases. Appl Sci. 2020; 10: 4852.

[40] Fabbro A, Prato M, Ballerini L. Carbon nanotubes in neuroregeneration and repair. Adv Drug Deliv Rev. 2013; 65: 2034-44.